Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancer
Wiem Lassoued(National Institutes of Health), James L. Gulley(National Cancer Institute), Jennifer L. Marté(National Cancer Institute), Yo-Ting Tsai(Comprehensive Blood & Cancer Center), Colin Pritchard, Peter A. Pinto(National Institutes of Health), Amy Hankin(National Institutes of Health), Ravi A. Madan(National Cancer Institute), Renee N. Donahue(National Institutes of Health), Zhigang Kang(National Cancer Institute), Jeffrey Schlom(National Cancer Institute), Fatima Karzai(National Institutes of Health), Elisabetta Xue(Vita-Salute San Raffaele University), William Dahut, Kenneth Canubas(National Institutes of Health), Michell Manu(Frederick National Laboratory for Cancer Research), Manuk Manukyan(Frederick National Laboratory for Cancer Research), Sam Sater(National Institutes of Health), Daniel Burnett(National Institutes of Health), Moniquea Williams(National Cancer Institute), Antonios Papanicolau-Sengo(National Cancer Institute), Shania Bailey(National Institutes of Health)
Cited by 8
Related Papers
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
|Blood|2005|896
Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast Tumors
|Hybridoma|1984|580
A spectrum of monoclonal antibodies reactive with human mammary tumor cells.
|Proceedings of the National Academy of Sciences|1981|563